Floatz logo

Selinexor

Advanced Malignant Solid Neoplasm

M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

124 Active assets in the Advanced Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Palbociclib
National Cancer Institute (NCI)
Phase 2BB
Olaparib
National Cancer Institute (NCI)
Phase 2BB
Nivolumab
National Cancer Institute (NCI)
Phase 2BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2B
Vinorelbine
OHSU Knight Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →